Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356093 | 1.00 | SLC7A5 (0.49) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL198638 | 1.00 | SLC7A5 (0.49) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL2059137 | 0.81 | ALDH1A1 (0.37) | SLC7A5CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5814493 | 0.80 | ALDH1A1 (0.39) | SLC7A5CYP3A4ALDH1A1 | |
| SCHEMBL21689933 | 0.75 | SLC7A5 (0.53) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL1769036 | 0.75 | SLC7A5 (0.53) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL1769034 | 0.75 | SLC7A5 (0.53) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| Hydrochloric Acid SCHEMBL20502478 | 0.73 | SLC7A5 (0.52) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL5828934 | 0.73 | KIF11 (0.38) | SLC7A5CYP3A4 | |
| SCHEMBL1891367 | 0.70 | GRIA2 (0.50) | SLC7A5CYP3A4PKMALPIPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020221795-A1 | METHODS FOR PRODUCTION OF ERGOTHIONEINE | DANMARKS TEKNISKE UNIVERSITET (DK) | 2020-11-05 | — | — | WO | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3194359-B1 | BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS | INTREXON CORP (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-10196428-B2 | Modification of cupredoxin derived peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-05 | — | — | US | disclosed |
| EP-2742153-B1 | PROTEIN AND PEPTIDE LIBRARIES | MASSACHUSETTS GEN HOSPITAL (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-1307214-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1297354-A | Dipeptide caspase inhibitors and use thereof | CYTOVIA INC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | SLC7A5 762/4885CYP3A4 3689/4885PKM 4563/4885 |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | SLC7A5 487/4885CYP3A4 3536/4885PKM 4561/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | SLC7A5 762/4885CYP3A4 3689/4885PKM 4563/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | SLC7A5 762/4885CYP3A4 3689/4885PKM 4563/4885 |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | BRDT, CD22, BCR | SLC7A5 487/4885CYP3A4 3536/4885PKM 4561/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | SLC7A5 4217/4885CYP3A4 3173/4885PKM 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.